,18 Fifth, the presence of chronic kidney disease (CKD) at baseline may influence the relationship between canagliflozin and levels of FGF-23 and hsCRP; this may be evaluated in SGLT2 inhibitor trials among patients with CKD. The gene discussed is FGF23; the disease is chronic kidney disease.